Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry

Dear Editor,

COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a threat to millions of lives worldwide. Although SARS-CoV-2 vaccines have been approved to reduce the severity and death associated with COVID-19, the number of SARS-CoV-2-infected cases still remains high, especially with the appearance of various mutant strains such as P.1.351 and P.1.617 (also known as South Africa strain and India strain, respectively), which may reduce the efficacy of vaccine protection. There is an urgent need to develop effective antiviral agents to treat COVID-19 patients, especially with those infected with SARS-CoV-2 variants of concern.

The goal of our study was to evaluate the SARS-CoV-2 antiviral activities of Food and Drug Administration (FDA)-approved drugs, which could accelerate the development of novel therapies for COVID-19. We tested tamoxifen and clomiphene which were also used to screen antiviral agents against flavivirus. On Vero and Caco-2 cells, we first measured the cytotoxicity of the two drugs and determined that their median cytotoxic concentrations (CC50s) in vitro were much higher than our experimental range (Supplementary Fig. S1a). Moreover, we analyzed the antiviral activities of the two drugs and found that both tamoxifen and clomiphene had effective antiviral activities. The median effective concentrations (EC50s) of tamoxifen and clomiphene on Vero cells were 1.634 and 0.3213 μM, respectively (Fig. 1a). The two drugs also suppressed SARS-CoV-2 infection in Caco-2 cells with a dose-dependent manner (Supplementary Fig. S1e, f). These results showed that tamoxifen and clomiphene strongly antagonized SARS-CoV-2 infection in vitro.

In addition to the EC50s calculated according to SARS-CoV-2 RNA copies in cell supernatants, we also measured the spike (S) protein levels of SARS-CoV-2 in infected cells under drug treatments. Vero cells were pretreated with tamoxifen or clomiphene of different doses, and then infected with SARS-CoV-2. Vero cells were continued to be treated with drugs after infection. SARS-CoV-2 S protein was used to test viral protein production by western blot. The results suggested that tamoxifen and clomiphene reduced SARS-CoV-2 S protein production, especially the accumulation of the S2 fragment (Fig. 1b, c). SARS-CoV-2 S protein was also examined under tamoxifen and clomiphene treatments by immunofluorescence (Fig. 1d, e). The results showed that the two drugs reduced SARS-CoV-2 S protein production in a dose-dependent manner, which further illustrated the antiviral activities of tamoxifen and clomiphene against SARS-CoV-2 infection.

To understand the mechanism responsible for the antiviral activities of tamoxifen and clomiphene against SARS-CoV-2 infection, we first measured the transcriptome of HuH7 cells which were either untreated or pretreated with tamoxifen or clomiphene before SARS-CoV-2 infection to determine the effects of these drugs on SARS-CoV-2-induced gene expression profiles. The transcriptome results showed that SARS-CoV-2 infection increased the expressions of interferon (IFN) and acute inflammatory response genes, but these inductions were suppressed by tamoxifen and clomiphene treatments (Supplementary Fig. S2a, b). To further determine whether tamoxifen and clomiphene directly suppressed IFN and inflammation response genes or indirectly affected IFN and inflammation responses through inhibiting SARS-CoV-2 infection, we also analyzed the effect of tamoxifen and clomiphene on poly(I:C)-induced IFN response genes. A549 cells were pretreated with tamoxifen and clomiphene before transfection with poly(I:C) and cells were collected for real-time quantitative reverse transcription PCR (qRT-PCR). The results showed that tamoxifen and clomiphene did not affect the poly(I:C)-induced IFN response genes including RIG-I, IFN-β, and IRF7 (Supplementary Fig. S3a–c), suggesting that tamoxifen and clomiphene control SARS-CoV-2 infection to reduce IFN and acute inflammatory responses.

To investigate the additional mechanisms by which tamoxifen and clomiphene inhibit SARS-CoV-2 infection, we applied the SARS-CoV-2 pseudovirus, which only contains the S protein of SARS-CoV-2 on the VSV backbone with a luciferase reporter. We found that tamoxifen and clomiphene strongly suppressed the infection of wide type (WT) SARS-CoV-2 pseudovirus in a dose-dependent manner (Fig. 1g). Moreover, we also found that tamoxifen and clomiphene strongly suppressed the infection of P.1.351 and P.1.617 pseudovirus (Fig. 1h, i). Toremifene, the analog of tamoxifen, was reported to treat COVID-19 by blocking S protein.1 We further explored whether the binding between S protein and the receptor of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), was affected under the treatment of tamoxifen and clomiphene. The binding activity measured by enzyme-linked immunosorbent assay (ELISA) showed that tamoxifen and clomiphene did not affect the binding between the receptor-binding domain (RBD) of SARS-CoV-2 and ACE2 proteins (Fig. 1f). Subsequently, we also tested the inhibition of tamoxifen and clomiphene against SARS-CoV-2 S protein-induced membrane fusion, the result showed that tamoxifen and clomiphene could suppress the membrane fusion which is an important early step for SARS-CoV-2 infection (Fig. 1j). Our study, therefore, suggested that tamoxifen and clomiphene inhibited the infection of SARS-CoV-2 and its variants in vitro through suppressing viral entry on the post-binding stage.

We further examined the inhibition of tamoxifen and clomiphene in mice. The SARS-CoV-2 mouse-adapted strain was used in our study as previously described.2 6-8-week-old BALB/c mice were treated by intraperitoneal injection of tamoxifen and clomiphene prior to infection intranasally with the SARS-CoV-2 mouse-adapted strain. The drug administrations were continued once daily until 3 days post infection (dpi), when the trachea and lung tissues of mice were collected for viral RNA loads assay. The results of the qRT-PCR assay showed that tamoxifen and clomiphene inhibited SARS-CoV-2 RNA loads in the trachea and lung (Fig. 1k, l). In consistent with the qRT-PCR results, we also carried out the SARS-CoV-2 genome RNA in situ hybridization (ISH) assay with RNAscope Reagent Kit. As shown in Fig. 1m, the SARS-CoV-2 genome RNAs while intensively accumulated on the lung

Received: 10 September 2021 Revised: 3 December 2021 Accepted: 6 December 2021
Published online: 21 December 2021

© The Author(s) 2021, corrected publication 2021
blood vessel wall of SARS-CoV-2-infected mice were strongly inhibited in mice treated with either tamoxifen or clomiphene. Finally, we examined the lung inflammation of SARS-CoV-2-infected mice and found that treatment of mice with either tamoxifen or clomiphene strongly decreased the mRNA levels of cytokines such as TNF-α and IL-6 and chemokines such as CXCL15 and MCP-1, in the lung of SARS-CoV-2-infected mice as measured by qRT-PCR (Supplementary Fig. S4a-d). The result of hematoxylin and eosin (H&E) staining of mice lung also showed that both drug treatments strongly reduced the lung tissue inflammation in the lung of SARS-CoV-2-infected mice (Fig. 1n). Above all, our study suggested that tamoxifen and clomiphene inhibited SARS-CoV-2
infection and reduced SARS-CoV-2-induced inflammatory response in mice. The outbreak of emerging infectious diseases presents huge global challenge to develop vaccines and drugs within very limited time period to control pandemic. In the case of COVID-19 pandemic, SARS-CoV-2 vaccines, such as inactive vaccine, mRNA vaccine, and adenovirus vector vaccine, have been approved in unprecedented speed to be used in people. However, it is unlikely that vaccine alone would be able to control this COVID-19 pandemic as multiple dominant SARS-CoV-2 mutant variants have been emerged, some of which can escape from antibody treatment or vaccine protection. In our study, we found that tamoxifen and clomiphene effectively suppressed the infection of not only WT but also mutant SARS-CoV-2 variants such as P.1.351 and P.1.617. These studies suggest that tamoxifen and clomiphene can be used as antiviral agents against different SARS-CoV-2 mutant variants. Furthermore, we have used the SARS-CoV-2-infected mouse model to demonstrate the antiviral activity and anti-inflammation activity of tamoxifen and clomiphene in vivo. Further studies are needed to evaluate the pro and con effects of using these FDA-approved drugs as a therapeutic option for treatment or prevention of infection by the currently circulating SARS-CoV-2 and other emerging coronaviruses in the future.

DATA AVAILABILITY
All data are available within the article, supplementary information, or available from the corresponding author upon reasonable request.

ACKNOWLEDGEMENTS
We thank Drs. Youchun Wang and Weijin Huang for providing the SARS-CoV-2 pseudovirus system. This project is supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2021-12M-1-047, 2019-12M-5-049 and 2016-12M-1-005), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT310-006, 2019XK310002, 2018TX31001, and 3332018131), the National Natural Science Foundation of China (91542201, 81925025, 82102371, 82174055, 82073181, 81802870, and 2017YFA0506200), and the National Key Research and Development Project (2020YFC0841700), as well as NIH R01AI069120, AI158154, and AI140718 grants, the UCLA AIDS Institute; and UCLA David Geffen School of Medicine–Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program. H.Y. is supported by science funds from Jiangsu Province (BK20211554, BK20170407) and the Innovative and Entrepreneurial Team grant (2018-2021) from Jiangsu Province. L.L. is supported by Innovative and Entrepreneurial Doctor grant (2020-2022) from Jiangsu Province. R.L. is supported by the Chinese Postdoctoral Science Foundation (2020T1301352X).

REFERENCES
1. Martin, W. R. & Cheng, F. Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2. J. Proteome Res. 19, 4670–4677 (2020).
2. Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369, 1603–1607 (2020).
3. Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 21, 181–192 (2021).
4. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
5. Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).

AUTHOR CONTRIBUTIONS
G.C., Y.-Q.D., and H.Y. conceived and designed the experiments. S.Z., L.L., Q.Y., and D. L. performed the majority of the experiments and analyzed the data. R-T.L. helped RNA sequencing experiments and data analysis. Y.W. helped ELISA experiments and data analysis. S.Z. wrote the original draft of the manuscript. D.L. and L.L. helped revise the manuscript. All authors read and approved the contents of the manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41392-021-00853-4.

Competing interests: The authors declare no competing interests.

Shulong Zu1,2,3,4, Dan Luo4, Li Li2,3, Qing Ye, Rui-Ting Li5, Yinan Wang6, Meling Gao6,3, Heng Yang5,6,7,8, Yong-Qiang Deng6,7,8 and Genhong Cheng1
1Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 3Suzhou Institutes of Medical Systems Science, Suzhou, Jiangsu, China; 4State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China; 5Suzhou Func Biotec Inc, Suzhou, Jiangsu, China and 6Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, USA

These authors contributed equally: Shulong Zu, Dan Luo, Li Li, Qing Ye.
Correspondence: Heng Yang (yhmyt@hotmail.com) or Yong-Qiang Deng (dengyq1977@126.com) or Genhong Cheng (gcheng@mednet.ucla.edu)
